SCHEMBL18359792

SCHEMBL18359792

CCCCOC[C@H]1O[C@@](O)(c2cnc3c(SC)nc(SC)nn23)C(F)[C@@H]1OCCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15259018 1.00 — —
SCHEMBL15259051 0.91 — —
SCHEMBL15289762 0.91 — —
SCHEMBL12453964 0.81 — —
SCHEMBL13532542 0.78 — —
SCHEMBL17131382 0.78 — —
SCHEMBL17130311 0.78 — —
SCHEMBL15259022 0.77 — —
SCHEMBL15259013 0.77 — —
SCHEMBL13667907 0.73 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210993-A1 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT Gilead Sciences, Inc. (US) 2017-08-30 — — EP disclosed
EP-2834258-B1 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES INC (US) 2017-01-04 — — EP disclosed
Send feedback